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Objective
To assess the long-term efﬁcacy and safety of polydimethylsiloxane
injection (Macroplastique, Cogentix Medical, Orangeburg,
New York, USA) for the treatment of female stress urinary
incontinence (SUI), with a minimum follow-up of 3 years.
Patients and Methods
This is an observational analytical prospective cohort study
conducted in a single uro-gynaecological unit. All consecutive
women with urodynamically conﬁrmed pure SUI treated with
the Macroplastique procedure, were included. Data regarding
patient outcomes (International Consultation on Incontinence
Questionnaire–Short Form, Patient Global Impression of
Improvement, and patient satisfaction scores), objective cure
rates, and adverse events were collected during follow-up.
Uni- and multivariable analyses were performed to investigate
outcomes. Multiple logistic regression was performed to
identify factors involved in the risk of failure of the
procedures or recurrence of SUI.
Results
In all, 85 women had the Macroplastique procedure. At the
3-year follow-up, all 85 (100%) patients were available for
the evaluation. We did not ﬁnd any signiﬁcant change in
the surgical outcomes during this time. At 3 years after
surgery, 42 of 85 patients (49%) declared themselves cured
(P = 0.67). Similarly, at the 3-year evaluation, 40 of 85
patients (47%) were objectively cured. There was no
signiﬁcant deterioration of objective cure rates over time (P
= 0.3). A history of radical pelvic surgery and a low
surgeon’s skill were signiﬁcantly associated with the risk of
failure of Macroplastique. The multivariate analysis
conﬁrmed these ﬁndings; a previous history of radical
pelvic surgery and a low surgeon’s skill independently
predicted the subjective and objective failure of
Macroplastique.
Conclusions
The 3-year results of this study showed that Macroplastique
could be an acceptable alternative for the treatment of SUI
with stable results over time and a negligible complication
rate.
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Introduction
Stress urinary incontinence (SUI) is the predominant form of
UI in women. Depending on age, the prevalence ranges from
29% to 75%, with a mean of 48% [1]. When ﬁrst-line
conservative management fails, surgery is required and
several surgical options for treating SUI are available.
Retropubic and transobturator tension-free mid-urethral
slings (MUS) are the most effective and commonly
performed procedures for the surgical treatment of female
SUI [2]. These techniques are currently the ‘gold standard’
treatment for SUI, even in comparison with Burch
colposuspension, as they are characterised by a global cure
rate of 84.4% at 12 months follow-up with long-lasting
beneﬁts [1,3,4]. After the 2008 USA Food and Drug
Administration (FDA) warning on the transvaginal
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placement of surgical mesh for the treatment of pelvic organ
prolapse, some criticisms also involved the adoption of
prosthetic material in the treatment of SUI [5]. Very
recently, the European Urology Association (EAU) stated a
Consensus on the use of implanted materials for treating
pelvic organ prolapse and SUI taking into account, amongst
others, the European Commission’s Scientiﬁc Committee on
Emerging and Newly Identiﬁed Health Risks (SCENIHR)
report on the use of surgical mesh. A key message from this
Consensus is that synthetic slings for SUI can be safely used,
provided that patients are aware of the alternative available
options including bulking agents, colposuspension, and
autologous sling surgery [6,7].
Bulking agents can be effectively considered an alternative
option in the management of female patients with SUI and
they are currently considered the ﬁrst-line surgical choice in
selected populations of incontinent women (i.e., patients
with comorbidities, high anaesthetic risk, in those who
prefer a less invasive approach) [8]. The growing interest
toward efﬁcacy and safety of urethral injection therapy, as
an alternative approach for the treatment of female SUI, is
witnessed by the publication in the last few years of various
systematic reviews and meta-analysis [8–11]. The Cochrane
systematic review by Kirchin et al. [9] outlines that ‘The
available evidence base remains insufﬁcient to guide
practice’. Heterogeneity of agents studied, small number of
cases, lack of comparison with other treatments or placebo,
and short follow-up, represent the major limitations of
available studies. At 12 months follow-up, a cure rate of
24.8% to 36.9% is reported but no data on a longer term
are available [1]. Moreover, no data on the reproducibility
and learning curve of the different materials and
implantation techniques are reported in the literature.
Interestingly, on the basis of the systematic review published
by Riemsma et al. [1] on cure rates for the available
treatment options for incontinence (UI and faecal), it
becomes evident that in the elderly population none of the
studies on UI reported cure rates beyond 3 months’ follow-
up. Particularly in this population, the advantages in terms
of reducing postoperative voiding dysfunction and
complication rates have to be clearly documented, even in
the long term [1,7].
Polydimethylsiloxane (Macroplastique, Cogentix Medical,
Orangeburg, New York, USA) is a minimally invasive bulking
agent, with reported efﬁcacy in the short-term (1-year) ranging
from 34.8% to 80% [10]. Very limited data are available on the
long-term follow-up, with Ghoniem et al. [12] reporting 67%
objective cure rate at 24 months follow-up of 75 women and
Tamanini et al. [13] in a smaller study (21 patients) claiming a
cure/improvement rate of 73.3% at 60 months.
The aim of the present study was to prospectively evaluate
long-term efﬁcacy and safety of Macroplastique with a
minimum follow-up of 3 years. Moreover, we assessed the
possible risk factors associated with a lower efﬁcacy of this
procedure.
Patients and methods
This was an observational analytical prospective cohort study
performed in a single Urogynecological Unit, between 2008
and 2014. We enrolled all consecutive women with pure SUI
symptoms and urodynamically conﬁrmed urodynamic SUI,
who received the Macroplastique procedure. Patients were
counselled between Macroplastique and MUS procedure; the
choice of the surgical method was based on the patient’s
preference.
Exclusion criteria were: preoperative clinically signiﬁcant
voiding dysfunction, a postvoid residual urine volume (PVR)
of >100 mL, documented recurrent UTIs, concomitant
vaginal prolapse > stage 1 according to the pelvic organ
prolapse quantiﬁcation (POP-Q) system, overactive bladder
(OAB) symptoms, urodynamically conﬁrmed detrusor
overactivity (DO). We also included women with previous
history of radical pelvic surgery. We excluded patients with a
concomitant relevant POP because these patients can present
several confounding variables, such as increased rate of
concomitant OAB, DO, and/or voiding dysfunction.
Preoperative evaluation included: medical history, physical
examination, a voiding diary, urine analysis, and complete
urodynamic testing. Physical examination was performed with
the patient in lithotomy and POP was described during a
maximal Valsalva manoeuvre according to the POP-Q system
[14]. All women were evaluated with urodynamic studies as
previously described [15] (including uroﬂowmetry, ﬁlling
cystometry, Valsalva leak-point pressure [VLPP]
measurement, and pressure/ﬂow study) by a trained
urogynaecologist, using a standardised protocol in accordance
with the Good Urodynamic Practices guidelines of the ICS
[16]. We evaluated the objective severity of SUI using the ‘1-
3-5 cough test’ during urodynamics [17]. Urethral
hypermobility was deﬁned by a Q-tip test >30°. Patients were
included regardless of Q-tip test and VLPP values. All
methods, deﬁnitions, and units were updated in agreement
with the last version of the ICS standardisation of
terminology [18]. All patients also completed the
International Consultation on Incontinence Questionnaire-
Short Form (ICIQ-SF) questionnaire [19] and Urogenital
Distress Inventory (UDI). One experienced urogynaecological
surgeon, according to the original technique, performed all
the urethral injections of Macroplastique. The ‘Macroplastique
Implantation System’ included: the Macroplastique
implantation device (MID) and two needles; the MID is a
sterile, 25 F, single-use device with a ﬂuid drainage channel
and three ﬁxed needle entry ports. A measuring scale for
determining urethral length during the procedure is printed
on MID. We inserted the MID tip into the urethra and
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advanced the tip into the bladder until ﬂuid ﬂowed from the
ﬂuid drainage channel. Then, we withdrew the MID 15 mm
and we injected 2.5 mL Macroplastique in the 6 o’clock
position, 1.25 mL in the 10 o’clock position, and 1.25 mL in
the 2 o’clock position [20,21]. Patients were allowed to go
home the same day when comfortable and voiding. If the
patient was unable to pass urine spontaneously within 3–4 h
of the procedure, ‘in and out catheterisation’ with a catheter
was performed to relieve any symptoms of urinary retention.
If PVRs of >100 mL were detected, the patient was followed-
up in the hospital until voiding. All procedures were
performed under general anaesthesia.
Postoperative evaluations were scheduled at 3-months, 1-, 2-,
3-years, and then every year. Every follow-up visit included
medical history, physical examination, voiding diary, stress
test, and evaluation of subjective satisfaction. A stress test was
performed in the lithotomy and upright positions with a full
bladder (ultrasonographic measurement >400 mL). Objective
cure was deﬁned as the absence of urine leakage during the
stress test. To deﬁne the subjective outcomes, all patients
completed the ICIQ-SF, the Patient Global Impression of
Improvement (PGI-I) Scale (a 7-point scale, with a range of
responses from 1, ‘very much improved,’ through to 7, ‘very
much worse’) [22], and a Patient Satisfaction Scale (a single,
self-answered, Likert-type scale of 0–10 that grades the
patient’s degree of satisfaction regarding continence: 0
represents ‘not satisﬁed,’ and 10, ‘satisﬁed’) [23]. Subjective
success was indicated both by ‘very much improved’ or ‘much
improved’ (PGI-I ≤2) and by a patient satisfaction score ≥8,
as previously described in 2011 by Abdel-Fattah et al. [24].
All other patients were considered as failures. Patients also
completed the ICIQ-SF and UDI at the 3-month and 3-year
follow-up visits. The Declaration of Helsinki was followed,
and preoperative written informed consent for
Macroplastique injection was obtained from all patients. A
local Institutional Review Board approval was obtained
(o.g.Va02/08). Data were prospectively collected into a
speciﬁcally designed digital database.
Statistical analysis
Statistical analysis was performed with the Statistical Package
for the Social Sciences (SPSS), version 17 for Windows
(SPSS Inc., IBM Corp., Armonk, NY, USA). Continuous
variables were reported as median and interquartile range
(IQR). We used the chi-squared test and chi-squared test for
trend to analyse and compare the surgical outcomes during
follow-up. The chi-squared test for trend can better assess if
the success of the surgical procedure tends to decrease over
time, comparing the cure rates at the different follow-up visits
(3-months, 3-years, and last follow-up). The null hypothesis
is that there is not an association between the cure rate of
Macroplastique and the time. One-way ANOVA was used to
compare continuous series of variables in the comparison of
the scores used to measure the subjective outcomes. Multiple
logistic regression was performed to identify factors involved
in the risk of failure of the procedures or recurrence of SUI.
The multivariate model included those variables that achieved
signiﬁcance (P < 0.05) or association (P ≤ 0.10) in the
univariate analysis. Statistical signiﬁcance was considered
achieved when P < 0.05.
Results
During the study period, 85 women with conﬁrmed SUI, who
fulﬁlled the inclusion criteria, had Macroplastique urethral
injections. Baseline characteristics of the study are
summarised in Tables 1 and 2. At the 3-year follow-up, 85
(100%) patients were available for evaluation. The mean (SD;
median) follow-up was 58 (22; 48) months. Subjective and
objective cure rates are summarised in Table 3. Table 4
reports the trend of the subjective outcomes scores over time.
Long-term data showed no signiﬁcant deterioration of either
subjective or objective outcomes. No patients received a
second injection of Macroplastique, as we preferred to offer a
MUS in case of failure and not a second bulking procedure.
Therefore, in the 12 cases of failure at the 3-month follow-up,
we performed a transobturator sling procedure 6 months
after Macroplastique injection, with objective and subjective
cure of SUI in all patients. Looking at factors inﬂuencing the
Table 1 Baseline characteristics.
Characteristic Value
Number of patients 85
Age, years, median (IQR) 64 (40–76)
BMI, kg/m2, median (IQR) 25.3 (23–28)
Obese (BMI ≥30 kg/m2), n (%) 13 (11)
Menopausal, n (%) 36 (42)
Previous vaginal deliveries, n, median (IQR) 1 (1–2)
Operative delivery (vacuum/forceps), n (%) 4 (5)
Previous radical pelvic surgery, n (%) 8 (9.4)
Previous anti-incontinence surgery, n (%) 9 (11)
BMI, body mass index.
Table 2 Preoperative urodynamic data.
Variable Median (range)
FDTV, mL, 180 (50–430)
CC, mL 480 (220–500)
PdetMax during ﬁlling phase, cmH2O 8.4 (3–15)
Qmax, mL/s 21 (7–77)
Intravesical opening pressure, cmH2O 23.4 (9–66)
PdetMax during voiding, cmH2O 31.5 (10–75)
PdetQMax, cmH2O 24.4 (8–60)
VLPP, cmH2O 64 (24–91)
CC, cystometric capacity; FDTV, ﬁrst desire to void; PdetMax, maximum detrusor
pressure; PdetQMax, detrusor pressure at maximum urinary ﬂow; Qmax, maximum
urinary ﬂow.
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Macroplastique failure rate, we found that a previous history
of radical pelvic surgery and a low surgeon’s skill (≤20
procedures, on the basis of the learning curve) were
signiﬁcantly associated with the risk of failure of
Macroplastique (Table 5). The multivariate analysis conﬁrmed
these ﬁndings; previous history of radical pelvic surgery and a
low surgeon’s skill independently predicted the subjective
(odds ratio [OR] 12.2, 95% CI 1.4–16.6, P = 0.02 and OR 3.8,
95% CI 1.3–11.0, P = 0.01, respectively) and objective failure
of Macroplastique (OR 11.8, 95% CI 1.6–17.2, P = 0.02 and
OR 3.6, 95% CI 1.2–10.2, P = 0.01, respectively).
Only one patient at the 3-month follow-up reported the onset
of de novo OAB symptoms. We administered antimuscarinics
treatment for 3 months with a total resolution of the
symptoms. The Clavien–Dindo Classiﬁcation of the
complications is shown in Table 6. We found only one case
of voiding dysfunction with a spontaneous resolution 3 days
after the procedure. Finally, one patient reported
postoperative urethral pain cured successfully with analgesic
drugs. No signiﬁcant POP or de novo dyspareunia were
registered in our study population.
Discussion
A durable effect over time after the Macroplastique
procedure, for the treatment of SUI, is the most striking
ﬁnding in our present study: women objectively and
subjectively cured after 3 months were still continent 3 years
later and remained dry even with protracted follow-up.
‘Nothing last forever?’ was the incipit of Peter Dwyer’s
Editorial, commenting on the ﬁrst report 17 years after a
TVT procedure [25,26]. Contrary to what is consistently
reported for MUS, with its durability further conﬁrmed in the
very long term [27], the success rate of bulking agents is
considered to be associated with a relevant deterioration over
time [10]. Zivanovich et al. [28], in a study adopting
polyacrylamide hydrogel (Bulkamid) in 60 women with
previously failed MUS reported a decrease in objective
efﬁcacy from 56.7% at 1 month to 43.3% and 25.4% after 6
and 12 months, respectively. Similarly, Zullo et al. [29],
reported on 27 patients treated with Macroplastique and
reported a decrease in objective cure rate from 55% at
6 months to 44% at 1 year. In addition, methodological
defects of the available studies on bulking agents are evident
and more stringent criteria for objective assessment have been
recommended [9,10]. Consequently, the concept of bulking
agents as a low efﬁcacy and transient cure for SUI has been
incorporated into guidelines [6]. Our present results disprove
this concept showing a not negligible and stable effect over
time of Macroplastique injections. In our present study, only
one highly trained surgeon performed the Macroplastique
injections, and this reduced the risk of failures due to
technical variation and different surgical experience.
We are quite conﬁdent in the results of our present study due
to its methodological strength: we included a relevant number
of women in a monocentric single-operator prospective study;
women underwent a structured objective and subjective
follow-up with a 100% follow-up rate at 3 years. Objective
cure was considered as the absence of urine leakage during a
stress test with a documented full bladder. Under these
circumstances, out of 85 women with conﬁrmed SUI, 53%
were objectively and subjectively cured after 3 months. At









Cured at last follow-up
(≥3 years), % (n/N)
P
Objective outcomes
53 (45/85) 51 (43/85) 48 (41/85) 47 (40/85) 47 (40/85) 0.9*
HR (95% CI) 1.3 (0.7–2.3) 0.4†
Subjective outcomes
53 (45/85) 51 (43/85) 51 (43/85) 51 (43/85) 49 (42/85) 0.67*
HR (95% CI) 1.1 (0.6–2.0) 0.44†
*Chi-squared test; †Chi-squared test for trend.
Table 4 Subjective outcomes scores at the 3-month, 3-year and at last follow-up visit.
Variable Baseline 3-months 3-years Last follow-up ≥3-year P
ICIQ-SF, median (IQR) 17 (16–17) 6 (0–17) 7 (0–17) 7 (0–17) 0.01*
‘Very much better’ or ‘much better’ on PGI-I, n/N (%) 55/85 (65) 54/85 (64) 51/85 (60)
Patient satisfaction scale, median (IQR) 8 (3–10) 8 (2–10) 7 (2–10)
80% reduction in UDI score, n/N (%) 56/85 (66) 54/85 (64) 51/85 (60)
*One-way ANOVA.
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3 years, the cure rate was 47%, which is not signiﬁcantly
different and remained the same both objectively and
subjectively, and also at a more prolonged follow-up with a
mean observation time of 58 months. In cases of failure, our
clinical policy was to propose a MUS and not a second
Macroplastique injection, with the aim to offer the most
effective treatment on the basis of the available studies in the
literature and to reduce the risk of a second failure.
Also, the role of the learning curve is worth commenting
upon in our present case series, as there was signiﬁcantly
inferior efﬁcacy for the ﬁrst 20 procedures. It is likely that,
with experience, the surgeon improves in ability to place the
material at the correct depth and length in the urethra
Injectable agents are commonly considered as a second-line
surgical treatment, limited to frail women not ﬁt, or not
willing to receive a traditional surgical procedure. Based on
these considerations, injectables tend to be adopted in few
cases, sometimes with different materials and procedures. The
scant quality of published data further supports the
impression of a non-systematic adoption of this surgical
approach [9]. As we documented, this aspect can have an
impact on the low efﬁcacy rate reported for bulking agents
[1,6].
In our present study, previous radical pelvic surgery was the
other predictor associated with a higher failure rate. These
women normally are considered to have a severe form of UI
with deﬁcient sphincter mechanism, commonly identiﬁed as a
ﬁxed urethra via a direct or indirect neurologically mediated
injury. Interestingly, in our present study, we failed to
demonstrate a correlation of failure with urethral mobility,
VLPP and severity of UI. Finally, a very low complication
rate has been conﬁrmed in our present study. Also, other
previously published studies demonstrated that
Macroplastique could also be equally effective in women with
a ﬁxed urethra [30]. We acknowledge that a possible
limitation of the present study could be that we included
procedures performed by only one highly trained surgeon and
therefore that our ﬁndings could be not applicable to every
other group. However, we also demonstrated that even an
expert surgeon requires a learning curve period to really offer
a good cure rate after a Macroplastique injection procedure.
Another possible limitation could be the lack of pad-weight
test and of the postoperative voiding diary results; however,
in this study we used many validated tools to evaluate and
describe the subjective and objective outcomes.
Conclusion
In an era when major surgery for SUI is under scrutiny due
to being too invasive or associated with an excessive
Table 5 Univariable analysis of variables potentially involved in the risk of failure of Macroplastique at 3 years.
Variable Subjective failure Objective failure
Univariable analysis* Univariable analysis*
HR (95% CI) P HR (95% CI) P
Elderly (age ≥65 years) 0.41 (0.23–1.14) 0.13 2.12 (0.84–5.73) 0.2
Obese (BMI ≥30 kg/m2) 1.84 (1.13–5.12) 0.05 1.53 (0.52–4.61) 0.5
Number vaginal deliveries (n ≥2) 0.42 (0.11–1.23) 0.3 0.80 (0.31–2.34) 0.8
Macrosome (≥4000 g) 0.71 (0.15–3.14) 0.6 0.63 (0.12–2.83) 0.5
Operative delivery 2.12 (0.63–7.62) 0.2 0.53 (0.07–3.91) 0.6
Menopausal 0.23 (0.03–1.70) 0.17 2.92 (0.34–4.33) 0.4
Previous anti-UI procedures 1.89 (0.44–8.11) 0.5 2.14 (0.64–9.7) 0.4
Previous radical oncological surgery 13.39 (1.66–18.4) 0.04 12.1 (1.32–13.45) 0.04
Surgeon’s skill (≤20 procedures) 3.51 (1.19–10.28) 0.02 1.52 (1.06–7.50) 0.03
Urethral mobility (Q-tip <30°) 1.53 (0.34–8.23) 0.8 1.41 (0.03–2.12) 0.3
VLPP <60 cmH2O 1.41 (0.39–6.88) 0.7 2.62 (0.81–3.42) 0.09
FDTV (≤180 mL) 3.1 (0.3–29.8) 0.32 4.2 (0.5–16.9) 0.20
CC (>480 mL) 1.9 (0.2–13.2) 0.52 2.8 (0.5–16.9) 0.25
PdetMax during ﬁlling phase (>9 cmH2O) 4.7 (0.5–45.5) 0.17 6.4 (0.7–57.1) 0.11
Qmax (≤24 mL/s) 5.6 (0.3–28.7) 0.95 5.6 (0.3–28.7) 0.95
Intravesical opening pressure (≤22 cmH2O) 6.2 (0.3–28.3) 0.95 2.6 (0.1–8.2) 0.95
PdetMax during voiding (≤29 cmH2O) 5.0 (0.1–14.2) 0.94 7.2 (0.8–64.4) 0.07
PdetQMax (>28 cmH2O) 0.95 (0.1–9.1) 0.96 1.8 (0.3–11.2) 0.48
Severity at UDI score 1.87 (0.56–4.32) 0.3 2.11 (0.91–3.22) 0.11
Severity at ‘1-3-5 cough test’ during UDS 1.4 (0.81–5.3) 0.5 1.2 (0.77–4.5) 0.62
CC, cystometric capacity; FDTV, ﬁrst desire to void; PdetMax, maximum detrusor pressure; PdetQMax, detrusor pressure at maximum urinary ﬂow; Qmax, maximum urinary ﬂow.
Signiﬁcant values in bold. *Univariate Cox proportional hazard model.
Table 6 Clavien–Dindo classiﬁcation of complications.
Clavien–Dindo
complication grade
N (%)(N = 85) Action
Grade I
Voiding dysfunction 1 (1.2%) Observation
Grade II
De novo OAB 1 (1.2%) Antimuscarinics
Urethral pain 1 (1.2%) Analgesic drugs.
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complication rate, alternative strategies for the surgical
treatment of SUI are welcome. Bulking agents can be
considered a realistic alternative, but the quality of the
evidence concerning their effectiveness, durability over time,
and associated morbidity is scant. With rigorous
methodological criteria, half of the women treated for SUI
were dry after a Macroplastique injection, with stable results
over time and a negligible complication rate. Our present
results are encouraging and suggest that bulking agents could
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